



CAMSON

## CAMSON BIO TECHNOLOGIES LIMITED

Bangalore  
February 12, 2015

To  
The Listing Department  
The Stock Exchange Mumbai  
25th Floor, Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001

Dear Sir / Madam

**Sub: Outcome of Board Meeting dated February 12<sup>th</sup> 2015**  
**Scrip Code: 538858**

In continuation to our intimation regarding the board meeting vide letter dated February 2, 2015, the Board of Directors of Camson Bio Technologies Limited, Bangalore transacted *inter alia* the following business:

1. Approval of the unaudited Financial Results for the Third Quarter and Nine months ended December 31, 2014 and the Limited Review Report issued by the Auditors has also been enclosed.

**2. Disclosure under Clause 25 of the Listing Agreement**

The Company has received In-Principle Approval from Bombay Stock Exchange Limited (BSE) for 14,99,990 Stock options under Employee Stock Option Plan 2012. The Board of Directors in their meeting held on February 12, 2015 as recommended by the Compensation committee in their meeting held on February 12, 2015 has granted the options to various eligible employees as under

- (a). Total Number of Options Granted: 14,99,990 (Fourteen Lakhs Ninety Nine Thousand Nine Hundred Ninety)
- (b). Exercise Price per Option: Rs. 109/- (One Hundred Nine Only)
- (c). The Vesting period of the options shall be as under

After the date of the grant, upon expiry of	% of Options which would vest
12 Months	33.34% of Options
24 Months	33.33% of Options
36 Months	33.33% of Options

Please treat this as compliance with the Listing Agreement.

Thanking you

For Camson Bio Technologies Limited

  
Dhirendra Kumar  
Managing Director  
DIN: 00301372



Regd. Office: SGNR-132, Madhure Hobli, Madagondanahalli, Doddaballapur, Bangalore-561203.  
Corporate Office : C-7, 7th Floor, Corporate Block, Golden Enclave, Old Airport Road,  
Bangalore - 560 017, Karnataka, INDIA. Ph : 080-25202283 / 84, 40768900, Fax : 080-25202285, 40768905  
Email : [info@camsonbiotechnologies.com](mailto:info@camsonbiotechnologies.com) Website : [www.camsonbiotechnologies.com](http://www.camsonbiotechnologies.com)  
CIN : L85110KA1993PLC014944, An ISO 9001:2008 Company



## Camson EBITDA jumps 59% during Q3 2014-15

Strong growth of 47% in Agri-biotech business

Knowledge driven farmer community spreading the message of Camson's Zero Residue solutions

### Financial Performance Highlights:

#### Q3 2014-15 compared with Q3 2013-14:

Revenues increase by 24% to Rs.54.6 crore from Rs.43.9 crore

EBITDA jumped 59% to Rs.7.6 crore compared to Rs.4.7crore

#### Segment Sales

Rs. Crore

	Q3 2014-15	Q3 2013-14	% Change
Seeds	33.9	29.8	14%
Agri-Biotech products	20.6	14.0	47%

#### Segment Results

Rs.Crore

	Q3 2014-15	Q3 2013-14	% Change
Seeds	3.3	4.6	-29%
Agri- Biotech products	3.5	2.2	57%

**Mumbai, February 12<sup>th</sup>, 2015:** Camson Bio Technologies Ltd., India's **IPR-driven** biotechnology company, posted a robust 24% growth in sales to Rs.54.6 cr during the Q3 of 2014-15. EBITDA jumped 59% to Rs.7.6 crore largely aided by the strong performance of the revolutionary agri-biotech business.

The agri-biotech business posted a smart 47% increase in sales to Rs.20.6 crore compared to Rs. 14 crore in Q3 of the previous year. In spite of the adverse climatic conditions witnessed in the southern states, the growing popularity of microbial based solutions and increasing number of touch points in northern India has boosted the growth and financial strength of the company. Brands like Calbahaar & Calnova did exceedingly well during the quarter.

Commenting on the results, **Santosh Nair, CEO at Camson Bio Technologies Ltd.** said "The strong performance of our technologically advanced products is a result of the increased acceptance by the knowledge driven farmer community. Word of mouth publicity of the success of these farmers has made Camson the preferred choice for Zero Residue Agriculture solutions. In spite of facing a challenging environment impacted by a poor monsoon and a cyclone in the southern states, team Camson has done exceedingly well". He also added "Performance benchmarks across departments – especially sales have been raised. The demerger of the seeds business is also on track and awaits clearances by the high court. This will bring about an improved focus on the promising agri-biotech business. All of these are initiatives to prepare Camson for the exciting times to come".





CAMSON

---

## Awards & Recognition

- Camson recognized by **Deloitte** as one of the fastest growing technology companies, a part of the Technology Fast 500 program.
- Camson awarded for “Responsible Business” and “Technology” by Inc India as recognition for exemplary growth.

+++

**About Camson Bio Technologies-** Established in 1993, Camson Bio Technologies Limited combines the latest knowledge in breeding, molecular genetics and metagenomics in agriculture with the latest practices in environmental safety and protection, to market a wide range of products spanning hybrid seeds, bio-fertilizers and biocides. These are non-poisonous, eco-friendly and residue-free. Headquartered in Bangalore, Camson Bio Technologies employs the best talent in the industry to bring innovative biotechnology products to the farmers. Partnering with farming communities, government agencies and corporate houses in India, Camson Bio Technologies aims at empowering farming communities by focussing its R&D to their needs.

++

For more information:

Sunil Ramakirshnan

**Rigveda consultancy & Services**

[sunil@rigvedaconsultancy.com](mailto:sunil@rigvedaconsultancy.com)

Mobile: - 09870110525



**CAMSON BIO TECHNOLOGIES LIMITED**  
**STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DEC 2014**  
**PART I**

Sl. No.	Particulars	Rupees in Lakhs						
		Consolidated						
		Quarter Ended		Nine months		Previous Year Ended		
31st Dec 2014 (Unaudited)	30th Sept 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Dec 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Mar 2014 (Audited)			
<b>1</b>	<b>Income from Operations</b>							
	(a) Net sales / Income from Operations (Net of Excise duty)	6,351.15	4,709.64	5,420.39	15,685.23	15,139.91	19,089.16	
	(b) Other Operating Income	-	-	-	-	-	-	
	<b>Total Income from Operations (net)</b>	<b>6,351.15</b>	<b>4,709.64</b>	<b>5,420.39</b>	<b>15,685.23</b>	<b>15,139.91</b>	<b>19,089.16</b>	
<b>2</b>	<b>Expenses</b>							
	(a) Cost of Materials consumed	765.66	1,721.97	879.69	3,179.61	1,660.90	2,104.56	
	(b) Purchase of stock-in-trade	874.80	2,414.60	1,677.25	4,323.99	6,953.08	9,320.98	
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	1,715.24	(2,428.94)	685.47	182.44	758.76	(332.76)	
	(d) Employee benefits expense	412.61	349.40	254.23	1,072.28	663.53	935.16	
	(e) Depreciation and amortisation expense	350.73	335.99	127.72	1,020.90	376.75	511.37	
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)							
	i Geo - Climatic Trials	136.47	138.73	145.08	465.70	298.94	410.59	
	ii Selling and Promotion Expenses	1,212.34	819.08	490.29	2,174.71	1,541.73	1,933.25	
	iii Other Expenses	481.68	1,223.74	810.14	2,342.51	1,711.71	2,246.44	
	<b>Total Expenses</b>	<b>5,949.53</b>	<b>4,574.57</b>	<b>5,069.87</b>	<b>14,762.14</b>	<b>13,965.40</b>	<b>17,129.59</b>	
<b>3</b>	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>401.62</b>	<b>135.07</b>	<b>350.52</b>	<b>923.09</b>	<b>1,174.51</b>	<b>1,959.57</b>	
<b>4</b>	Other Income	35.15	15.10	5.11	51.80	49.01	53.32	
<b>5</b>	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>436.77</b>	<b>150.17</b>	<b>355.63</b>	<b>974.89</b>	<b>1,223.52</b>	<b>2,012.89</b>	
<b>6</b>	Finance Cost	102.06	83.96	90.23	301.25	265.45	387.59	
<b>7</b>	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)</b>	<b>334.71</b>	<b>66.21</b>	<b>265.40</b>	<b>673.64</b>	<b>958.07</b>	<b>1,625.30</b>	
<b>8</b>	Exceptional Items	-	-	-	-	356.30	356.30	
<b>9</b>	<b>Profit / (Loss) from ordinary activities before tax (7 + 8)</b>	<b>334.71</b>	<b>66.21</b>	<b>265.40</b>	<b>673.64</b>	<b>601.77</b>	<b>1,269.00</b>	
<b>10</b>	Tax Expense	189.91	44.18	22.00	110.68	88.45	(47.90)	
<b>11</b>	<b>Net Profit / (Loss) from Ordinary Activities after tax (9 + 10)</b>	<b>144.80</b>	<b>22.03</b>	<b>243.40</b>	<b>562.96</b>	<b>513.32</b>	<b>1,316.90</b>	
<b>12</b>	Extraordinary Items (net of tax expenses)	-	-	-	-	-	-	
<b>13</b>	<b>Net Profit / (Loss) for the period (11 + 12)</b>	<b>144.80</b>	<b>22.03</b>	<b>243.40</b>	<b>562.96</b>	<b>513.32</b>	<b>1,316.90</b>	
<b>14</b>	Share of Profit / (Loss) of associates	-	-	-	-	-	-	
<b>15</b>	Minority Interest	(30.26)	(1.32)	0.34	(36.12)	0.71	(0.88)	
<b>16</b>	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)</b>	<b>114.54</b>	<b>20.71</b>	<b>243.06</b>	<b>526.84</b>	<b>512.61</b>	<b>1,316.02</b>	
<b>17</b>	Paid up Equity Share Capital (Face value of the Share is Rs. 10/-)	2,999.98	2,999.98	2,522.55	2,999.98	2,522.55	2,522.55	
<b>18</b>	Reserves excluding Revaluation Reserve as per Balance Sheet of the Previous Accounting Year	-	-	-	-	-	17,904.22	
<b>19.i</b>	<b>Earning per share (before extraordinary items) (of Rs.10 /- each) (not annualised): Rs</b>							
	(a) Basic	0.58	0.08	0.96	2.00	1.03	5.61	
	(b) diluted	0.58	0.08	0.79	2.00	1.03	4.79	
<b>19.ii</b>	<b>Earning per share (after extraordinary items) (of Rs.10 /- each) (not annualised): Rs</b>							
	(a) Basic	0.58	0.08	0.96	2.00	2.03	5.61	
	(b) diluted	0.58	0.08	0.79	2.00	1.66	4.79	



CAMSON BIO TECHNOLOGIES LIMITED  
PART II - SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED AS ON 31ST DEC 2014

Sl. No.	Particulars	Consolidated							Previous Year Ended 31st Mar 2014 (Audited)
		Quarter Ended			Nine months				
		31st Dec 2014 (Unaudited)	30th Sept 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Dec 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Mar 2014 (Audited)		
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>								
1	Public Shareholding - Number of Shares *	2,26,61,240 75.54%	2,26,61,240 75.54%	1,85,86,913 73.68%	2,26,61,240 73.54%	1,85,86,913 73.68%	1,85,86,913 73.68%	1,85,86,913 73.68%	
2	Promoters and Promoter group shareholding								
a)	Pledged/Encumbered - Number of Shares	0%	0%	0%	0%	0%	0%	0%	
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0%	0%	0%	0%	0%	0%	0%	
	Percentage of shares ( as a % of the total share capital of the company)	0%	0%	0%	0%	0%	0%	0%	
b)	Non-encumbered								
	Number of shares	73,38,600	73,38,600	66,38,600	73,38,600	66,38,600	66,38,600	66,38,600	
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	
	Percentage of Shares (as a % of the total share Capital of the Company)	24.46%	24.46%	26.32%	24.46%	26.32%	26.32%	26.32%	

Sl. No.	Particulars
<b>B</b>	<b>INVESTOR COMPLAINTS</b>
	Pending at the beginning of the quarter
	Received during the quarter
	Disposed of during the quarter
	Remaining unresolved at the end of the quarter



*(Handwritten mark)*

**CAMSON BIO TECHNOLOGIES LIMITED**  
**REPORT OF SEGMENT-WISE CONSOLIDATED REVENUE, RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR QUARTER AND NINE MONTHS ENDED AS ON 31ST DEC 2014**

Sl. No.	Particulars	Consolidated							Previous Year Ended 31st Mar 2014 (Audited)
		Quarter Ended			Nine months				
		31st Dec 2014 (Unaudited)	30th Sept 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Dec 2014 (Unaudited)	31st Dec 2013 (Unaudited)			
1	<b>Segment Revenue</b>								
	a) Seeds	4,206.48	2,424.65	4,021.66	10,229.87	11,595.37	14,754.88		
	b) Agribiotech Products	2,014.98	2,284.99	1,398.73	5,325.67	3,544.54	4,334.28		
	c) Others	129.69	-	-	129.69	-	-		
	<b>Total</b>	<b>6,351.15</b>	<b>4,709.64</b>	<b>5,420.39</b>	<b>15,685.23</b>	<b>15,139.91</b>	<b>19,089.16</b>		
	Less: Intersegment Revenue								
	<b>Net Sales/ Income from Operation</b>	<b>6,351.15</b>	<b>4,709.64</b>	<b>5,420.39</b>	<b>15,685.23</b>	<b>15,139.91</b>	<b>19,089.16</b>		
2	<b>Segment Results</b>								
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>								
	a) Seeds	391.79	(78.31)	459.72	795.21	893.37	2,085.93		
	b) Agribiotech Products	284.25	479.04	225.03	856.15	525.32	432.42		
	c) Others	(21.50)	-	-	(21.50)	-	-		
	<b>Total</b>	<b>654.54</b>	<b>400.73</b>	<b>684.75</b>	<b>1,629.86</b>	<b>1,418.69</b>	<b>2,518.35</b>		
	Less: (i) Other Net unallocated Income /expenses	217.77	250.56	325.78	654.97	551.46	861.76		
	(ii) Finance Cost	102.06	83.96	93.57	301.25	265.45	387.59		
	<b>Total Profit before Tax</b>	<b>334.71</b>	<b>66.21</b>	<b>265.40</b>	<b>673.64</b>	<b>601.78</b>	<b>1,269.00</b>		
3	<b>Capital Employed</b> (Segment Assets-Segment Liabilities)								
	a) Seeds	13,308.60	13,079.65	12,498.87	13,308.60	12,498.87	15,907.38		
	b) Agri Biotech products	9,644.85	8,863.12	7,654.69	9,644.85	7,654.69	5,435.09		
	c) Others	3,348.95	4,184.57	1,669.93	3,348.95	1,669.93	1,395.34		
	<b>TOTAL</b>	<b>26,302.40</b>	<b>26,127.34</b>	<b>21,823.49</b>	<b>26,302.40</b>	<b>21,823.49</b>	<b>22,737.81</b>		



→

**CAMSON BIO TECHNOLOGIES LIMITED**

Notes :

1. The above Financial Results were reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at it's meeting held on 12th February 2015.
2. The Company has opted to publish only unaudited standalone Financial Results. The unaudited consolidated Financial Results for the quarter ended Dec.31, 2014 of the Company will be available on the website of the Company and BSE.
3. The nature of the company's business being related to agriculture and the composition of income varying due to the underlying environmental and market conditions, the results of the company quarter on quarter can vary significantly and are therefore not comparable.
4. The Company has revised depreciation rates on fixed assets effective April 1, 2014 in accordance with requirement of schedule II of Companies Act 2013 ("the Act"). The remaining useful life has been revised by adopting standard useful life as per the Companies Act, 2013. Consequent upon such change the depreciation amounting to Rs.90.84 lakhs (net of deferred tax of Rs. 8.91 lakhs) has been adjusted against reserves in respect of assets which have already completed their useful lives before April 2014 and for other assets depreciation has been charged based on their remaining useful life. Had the company continued with the previously assessed useful lives, the charge for depreciation would have been lower by Rs.112 lakhs and Rs.270 lakhs for the quarter and nine months ended 31st December 2014 respectively.
5. Pursuant to the Scheme of Arrangement (the "Scheme") under Section 391 to 394 of the Companies Act 1956, the Board of Directors of Camson Bio Technologies Limited (the "Company" or "Camson"), had approved the demerger of Seeds business of Camson Bio Technologies Limited to Camson Seeds Limited. The Appointed date of the Scheme will be April 1, 2014 subject to approval by the Hon'ble High Court of Karnataka. On approval of the Scheme by the Honourable High Court, shareholders of Camson Bio Technologies Limited will get one equity share of Camson Seeds Limited for every share held in Camson Bio Technologies Limited. Camson Seeds Limited is proposed to be listed on the BSE, being the exchange where Camson is currently listed. The Company has filed the scheme with Bombay Stock Exchange (BSE) under clause 24(f) of the listing agreement and is in the process of filing the scheme with the Hon'ble High Court.

Financial results of discontinuing operation, subject to approval of the scheme by the Honourable High Court, under Accounting Standard 24 is given below :-

PARTICULARS	NINE MONTHS	
	QE DEC 2014	QE SEP 2014
REVENUE	33,98,48,770	19,48,55,653
EMPLOYEE BENEFIT COST	92,82,995	69,41,845
DEPRECIATION	1,38,80,469	1,31,21,413
FINANCE COST	46,66,535	24,94,257
OTHER EXPENSES	8,77,97,045	7,68,89,735
NET PROFIT	1,36,51,523	(1,24,10,465)

6. The Board of Directors at their meeting held on 12th February 2015, have granted 14,99,990 employee stock options as recommended by the Compensation committee at an exercise price of Rs.109 per option.
7. The Company operates in two segments i.e. Seeds and Agribiotech products
8. Figures for the previous periods/years have been regrouped/rearranged wherever necessary.

  
 For and on behalf of the Board of Directors  
**DHIRENDRA KUMAR**  
 Managing Director

Date : 12.02.2015  
Place: Bangalore

The Board of Directors  
Camson Bio Technologies Limited  
Survey No. 132,  
Madagondanahalli,  
Nelamangala Road,  
Doddaballapur,  
Bangalore 561 023.

Dear Sirs,

### LIMITED REVIEW REPORT

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Camson Bio Technologies Limited** for the quarter and nine months ended December 31, 2014, (the Statement) except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' and encumbrances thereon, which have been traced from the disclosures made by the Management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed By The Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We did not review the interim financial results of the subsidiary included in the consolidated unaudited financial results, whose interim financial statements reflect total assets of Rs. 371,777,051/- as at 31 December 2014 and revenues of Rs. 252,407,344/- for the period then ended respectively. These interim financial results have been reviewed by other auditor whose report has been furnished to us. Our conclusion on the consolidated unaudited financial results, in so far as it relates to such subsidiary is based solely on the report of the other auditor.

**Pune**

T + 91 020 60601005/6/7/8/9  
+ 91 020 25666932/32926341

E bkkpune@bkkhareco.com

Hotel Swaroop, 4th Floor,  
Lane No.10, Prabhat Road,  
Erandwane, Pune - 411 004, India

**Bengaluru**

T + 91 80 41105357

E bkkbengaluru@bkkhareco.com

101, Money Chambers,  
1st Floor, # 6 K. H. Road,  
Shanthinagar,  
Bengaluru - 560027, India

**New Delhi**

T + 91 011 4182 8360

E bkkdelhi@bkkhareco.com

107, Siddharth Chambers,  
Near IIT Gate,  
Kalu Sarai, Hauz Khas,  
New Delhi - 110 016. India.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with the Accounting Standards notified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of  
B. K. Khare & Co.  
Chartered Accountants  
Firm Registration No. 105102W



Viswanadh VNSS Kuchi  
Partner  
Membership No. 210789

Bangalore  
Date: 12 February 2015

**CAMSON BIO TECHNOLOGIES LIMITED**  
**STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DEC 2014**

PART I

Sl. No.	Particulars	Standalone							Previous Year Ended 31st Mar 2014 (Audited)
		Quarter Ended		Nine months					
		31st Dec 2014 (Unaudited)	30th Sept 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Dec 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Dec 2014 (Unaudited)	31st Dec 2013 (Unaudited)	
1	Income from Operations	5,458.51	4,156.96	4,388.36	13,188.46	10,651.80	14,562.78		
	(a) Net sales / income from Operations (Net of Excise duty)								
	(b) Other Operating Income								
	<b>Total income from Operations (net)</b>	<b>5,458.51</b>	<b>4,156.96</b>	<b>4,388.36</b>	<b>13,188.46</b>	<b>10,651.80</b>	<b>14,562.78</b>		
2	Expenses								
	(a) Cost of Materials consumed	690.52	1,730.02	887.40	3,109.38	1,668.85	2,131.52		
	(b) Purchase of stock- in-trade	165.00	1,933.07	673.46	2,104.56	2,568.55	4,866.83		
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	1,729.55	(2,445.84)	685.47	181.11	758.76	(291.73)		
	(d) Employee benefits expense	344.72	325.21	231.29	955.88	600.99	856.76		
	(e) Depreciation and amortisation expense	335.51	335.92	127.70	1,005.53	376.72	511.30		
	(f) Other expenses (Any Item exceeding 10% of the total expenses relating to continuing operations to be shown separately)								
	i Geo - Climatic Trials	136.47	138.73	145.08	465.70	298.94	410.59		
	ii Selling and Promotion Expenses	1,212.01	810.23	490.51	2,181.04	1,540.00	1,931.16		
	iii Other Expenses	424.32	1,206.18	798.39	2,251.19	1,667.44	2,189.45		
	<b>Total Expenses</b>	<b>5,038.10</b>	<b>4,033.52</b>	<b>4,039.30</b>	<b>12,254.39</b>	<b>9,480.25</b>	<b>12,605.88</b>		
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>420.41</b>	<b>123.44</b>	<b>349.06</b>	<b>934.07</b>	<b>1,171.55</b>	<b>1,956.90</b>		
4	Other income	32.34	13.10	5.11	46.83	49.01	53.28		
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>452.75</b>	<b>136.54</b>	<b>354.17</b>	<b>980.90</b>	<b>1,220.56</b>	<b>2,010.18</b>		
6	Finance Cost	73.04	67.17	90.23	247.52	265.44	386.86		
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)</b>	<b>379.71</b>	<b>69.37</b>	<b>263.94</b>	<b>733.38</b>	<b>955.12</b>	<b>1,623.32</b>		
8	Exceptional items								
9	<b>Profit / (Loss) from ordinary activities before tax (7 + 8)</b>	<b>379.71</b>	<b>69.37</b>	<b>263.94</b>	<b>733.38</b>	<b>955.12</b>	<b>1,623.32</b>		
10	Tax Expense	184.18	43.60	21.56	110.68	87.56	(60.10)		
11	<b>Net Profit / (Loss) from Ordinary Activities after tax (9 + 10)</b>	<b>195.53</b>	<b>25.77</b>	<b>242.38</b>	<b>622.70</b>	<b>511.26</b>	<b>1,327.12</b>		
12	Extraordinary items (net of tax expenses)								
13	<b>Net Profit / (Loss) for the period (11 + 12)</b>	<b>195.53</b>	<b>25.77</b>	<b>242.38</b>	<b>622.70</b>	<b>511.26</b>	<b>1,327.12</b>		
14	Share of Profit / loss of associates								
15	Minority interest								
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)</b>	<b>195.53</b>	<b>25.77</b>	<b>242.38</b>	<b>622.70</b>	<b>511.26</b>	<b>1,327.12</b>		
17	Paid up Equity Share Capital (Face value of the Share is Rs. 10/-)	2,999.98	2,999.98	2,522.55	2,999.98	2,522.55	2,522.55		
18	Reserves excluding Revaluation Reserve as per Balance Sheet of the Previous Accounting Year						17,863.38		
19.i	<b>Earning per share (before extraordinary items) (of Rs.10 /- each) (not annualised): Rs</b>								
	(a) Basic	0.65	0.09	0.96	2.08	2.03	5.65		
	(b) diluted	0.65	0.09	0.79	2.08	1.66	4.72		
19.ii	<b>Earning per share (after extraordinary items) (of Rs.10 /- each) (not annualised): Rs</b>								
	(a) Basic	0.65	0.09	0.96	2.08	2.03	5.65		
	(b) diluted	0.65	0.09	0.79	2.08	1.66	4.72		



*(Handwritten signature)*

*(Handwritten mark)*

CAMSON BIO TECHNOLOGIES LIMITED  
PART II SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED AS ON 31ST DEC 2014

Sl. No.	Particulars	Standalone							Previous Year Ended
		Quarter Ended			Nine months				
		31st Dec 2014 (Unaudited)	30th Sept 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Dec 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Mar 2014 (Audited)		
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>								
1	Public Shareholding	2,26,61,240	2,26,61,240	1,85,86,913	2,26,61,240	1,85,86,913	1,85,86,913		
	- Number of Shares *	75.54%	75.54%	73.68%	75.54%	73.68%	73.68%		
2	Percentage of Shareholding								
	Promoters and Promoter group shareholding								
a)	Pledged/Encumbered - Number of Shares	0%	0%	0%	0%	0%	0%		
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0%	0%	0%	0%	0%	0%		
	Percentage of shares ( as a % of the total share capital of the company)	0%	0%	0%	0%	0%	0%		
b)	Non-encumbered								
	Number of shares	73,38,600	73,38,600	66,38,600	73,38,600	66,38,600	66,38,600		
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%		
	Percentage of Shares (as a % of the total share Capital of the Company)	24.46%	24.46%	26.32%	24.46%	26.32%	26.32%		

B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	One
	Disposed of during the quarter	One
	Remaining unresolved at the end of the quarter	Nil



Handwritten signature or initials in blue ink.

**CAMSON BIO TECHNOLOGIES LIMITED**  
**REPORT OF SEGMENT-WISE CONSOLIDATED REVENUE, RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR QUARTER AND NINE MONTHS ENDED AS ON 31ST DEC 2014**

Sl. No.	Particulars	Rupees in Lakhs						Previous Year Ended
		Standalone			Nine months			
		31st Dec 2014 (Unaudited)	30th Sept 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Dec 2014 (Unaudited)	31st Dec 2013 (Unaudited)	31st Mar 2014 (Audited)	
<b>1</b>	<b>Segment Revenue</b>							
	a) Seeds	3,398.48	1,948.56	2,983.57	7,899.30	7,100.79	10,260.12	
	b) Agribiotech Products	2,060.03	2,208.40	1,404.79	5,289.16	3,551.01	4,302.66	
	c) Others	-	-	-	-	-	-	
	<b>Total</b>	<b>5,458.51</b>	<b>4,156.96</b>	<b>4,388.36</b>	<b>13,188.46</b>	<b>10,651.80</b>	<b>14,562.78</b>	
	Less: intersegment Revenue							
	<b>Net Sales/ Income from Operation</b>	<b>5,458.51</b>	<b>4,156.96</b>	<b>4,388.36</b>	<b>13,188.46</b>	<b>10,651.80</b>	<b>14,562.78</b>	
<b>2</b>	<b>Segment Results</b>							
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>							
	a) Seeds	325.41	22.09	459.36	829.75	891.51	2,058.95	
	b) Agribiotech Products	352.57	365.01	223.96	813.58	524.25	443.53	
	<b>Total</b>	<b>677.98</b>	<b>387.10</b>	<b>683.32</b>	<b>1,643.33</b>	<b>1,415.76</b>	<b>2,502.48</b>	
	Less: (i) Other Net unallocated Income /expenses	225.23	250.56	329.15	662.43	551.50	848.60	
	(ii) Finance Cost	73.04	67.17	90.23	247.52	265.44	386.86	
	<b>Total Profit before Tax</b>	<b>379.71</b>	<b>69.37</b>	<b>263.94</b>	<b>733.38</b>	<b>598.82</b>	<b>1,267.02</b>	
<b>3</b>	<b>Capital Employed</b>							
	(Segment Assets-Segment Liabilities)							
	a) Seeds	13,291.38	13,041.98	12,447.37	13,291.38	12,447.37	12,908.54	
	b) Agri Biotech products	9,644.85	8,863.12	7,654.69	9,644.85	7,654.69	8,633.73	
	c) Others	3,348.95	4,184.69	1,669.93	3,348.95	1,669.93	1,154.69	
	<b>TOTAL</b>	<b>26,285.18</b>	<b>26,089.79</b>	<b>21,771.99</b>	<b>26,285.18</b>	<b>21,771.99</b>	<b>22,696.96</b>	



*Handwritten signature in blue ink.*

*Handwritten mark in blue ink.*

**CAMSON BIO TECHNOLOGIES LIMITED**

**Notes :**

1. The above Financial Results were reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its meeting held on 12th February 2015.
2. The Company has opted to publish only unaudited standalone Financial Results. The unaudited consolidated Financial Results for the quarter ended Dec 31, 2014 of the Company will be available on the website of the Company and BSE.
3. The nature of the company's business being related to agriculture and the composition of income varying due to the underlying environmental and market conditions, the results of the company quarter on quarter can vary significantly and are therefore not comparable.
4. The Company has revised depreciation rates on fixed assets effective April 1, 2014 in accordance with requirement of schedule II of Companies Act 2013 ("the Act"). The remaining useful life has been revised by adopting standard useful life as per the Companies Act, 2013. Consequent upon such change the depreciation amounting to Rs.90.84 lakhs (net of deferred tax of Rs. 8.91 lakhs) has been adjusted against reserves in respect of assets which have already completed their useful lives before April 2014 and for other assets depreciation has been charged based on their remaining useful life. Had the company continued with the previously assessed useful lives, the charge for depreciation would have been lower by Rs.112 lakhs and Rs.270 lakhs for the quarter and nine months ended 31st December 2014 respectively.
5. Pursuant to the Scheme of Arrangement (the "Scheme") under Section 391 to 394 of the Companies Act 1956, the Board of Directors of Camson Bio Technologies Limited (the "Company" or "Camson"), had approved the demerger of Seeds business of Camson Bio Technologies Limited to Camson Seeds Limited. The Appointed date of the Scheme will be April 1, 2014 subject to approval by the Hon'ble High Court of Karnataka. On approval of the Scheme by the Honourable High Court, shareholders of Camson Bio Technologies Limited will get one equity share of Camson Seeds Limited for every share held in Camson Bio Technologies Limited. Camson Seeds Limited is proposed to be listed on the BSE, being the exchange where Camson is currently listed. The Company has filed the scheme with Bombay Stock Exchange (BSE) under clause 24(f) of the listing agreement and is in the process of filing the scheme with the Hon'ble High Court.

Financial results of discontinuing operation, subject to approval of the scheme by the Honourable High Court, under Accounting Standard 24 is given below :-

PARTICULARS	QE DEC 2014	QE SEP 2014	NINE MONTHS ENDED DEC 2014
REVENUE	33,98,48,770	19,48,55,653	78,99,30,559
EMPLOYEE BENEFIT COST	92,82,995	69,41,845	2,41,88,640
DEPRECIATION	1,38,80,469	1,31,21,413	4,12,94,707
FINANCE COST	46,66,535	24,94,257	1,48,26,219
OTHER EXPENSES	8,77,97,045	7,68,89,735	21,80,24,010
NET PROFIT	1,36,51,523	(1,24,10,465)	2,84,69,050

6. The Board of Directors at their meeting held on 12th February 2015, have granted 14,99,990 employee stock options as recommended by the Compensation committee at an exercise price of Rs.109 per option.
7. The Company operates in two segments i.e. Seeds and Agribiotech products.
8. Figures for the previous periods/years have been regrouped/rearranged wherever necessary.



For and on behalf of the Board of Directors

DHIRENDRA KUMAR  
Managing Director

Date : 12.02.2015  
Place: Bangalore

The Board of Directors  
Camson Bio Technologies Limited  
Survey No. 132,  
Madagondanahalli,  
Nelamangala Road,  
Doddaballapur,  
Bangalore 561 023.

Dear Sirs,

### LIMITED REVIEW REPORT

1. We have reviewed the accompanying statement of unaudited financial results of **Camson Bio Technologies Limited** for the quarter and nine months ended December 31, 2014, (the Statement) except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' and encumbrances thereon, which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Pune**

T + 91 020 60601005/6/7/8/9  
+ 91 020 25666932/32926341

E bkkpune@bkkhareco.com  
Hotel Swaroop, 4th Floor,  
Lane No.10, Prabhat Road,  
Erandwane, Pune - 411 004, India

**Bengaluru**

T + 91 80 41105357  
E bkkbengaluru@bkkhareco.com

101, Money Chambers,  
1st Floor, # 6 K. H. Road,  
Shanthinagar,  
Bengaluru - 560027, India

**New Delhi**

T + 91 011 4182 8360  
E bkkdelhi@bkkhareco.com

107, Siddharth Chambers,  
Near IIT Gate,  
Kalu Sarai, Hauz Khas,  
New Delhi - 110 016. India.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the Accounting Standards notified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of  
B. K. Khare & Co.  
Chartered Accountants  
Firm Registration No: 105102W



Viswanadh VNSS Kuchi  
Partner  
Membership No. 210789

Bangalore  
Date: 12 February 2015